Zydus LifeSciences delivered a better-than-expected financial performance in Q4, with 9.5%/19%/11% beat on revenue/Ebitda/PAT.
Source link
Zydus LifeSciences Shares in Focus: Motilal Oswal Maintains Neutral Rating on Limited Upside — Check Revised Target Price
Leave a comment